The authors discuss how more efforts need to ensure the methods used to measure the “value” of new therapies include factors that reflect patient heterogeneity.
Amy Miller, PhD
Advertisement
Articles by Amy Miller, PhD
Advertisement
Latest Updated Articles
- Why Accounting for Our Differences Matter in Assessing Drug Value
Published: June 1st 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
5
